Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hovione to acquire Pfizer’s Loughbeg API facility
Hovione Cork will employ 70-80 staff and will, over the next 24 months, be transferring products from its Loures, Portugal site and validating processes for new compounds in
Hovione Cork will employ 70-80 staff and will, over the next 24 months, be transferring products from its Loures, Portugal site and validating processes for new compounds in
The product is sold in a 40ml spray bottle that if used as directed is a two-month supply. Ralph Massa, Jr, Bi-Coastal Pharmaceutical’s president and COO, said: “I
The new product line contains five SKUs in the anti-hair loss shampoo, anti-hair loss treatment and hair gel categories, the company said. Genomma Lab acquired the Ma Evans
According to the company, the new location provides proximity to the large population center of Mexico City, easy access to the Ministry of Health and the ability to
Isoline leads are steroid eluting, dual coil defibrillation leads available in two fixation and two lengths models. With a fully isodiametric 7.8F lead body, Isoline leads include Easyturn:
Currently, ReceptoPharm is focused on developing novel therapies for neurological, viral, and autoimmune disorders. The contract from Celtic Biotech represents the first of such for the company. Completing
The first study, conducted by the Gruppo Italiano Malattie Ematologiche dell Adulto (GIMEMA), is an ongoing, open-label, single-stage, multicenter Phase II clinical trial, designed to evaluate the therapeutic
The patients in this Phase II clinical trial are in complete hematological remission following intense chemotherapy regimens, but retain acute lymphoblastic leukemia (ALL) cancer cells in their bone
In July 2008, Inovio and VGX Pharmaceuticals executed a definitive merger agreement, which provides for the issuance of Inovio’s securities in exchange for all of the outstanding securities
At the time of reporting, nine patients were evaluable. Overall, the objective response rate was 67%, with 33% of patients having a complete response. For the subgroup of